Supporting COVID-19 vaccination safety and reporting

Providing Australian health professionals and consumers with evidence-based information to support quality use of COVID-19 vaccinations

Supporting COVID-19 vaccination safety and reporting

Please note: Information, evidence and advice relating to COVID-19 is constantly changing. The information on this page was correct at the time of writing.

 

Key points

  • More than 63 million doses of COVID-19 vaccines have now been administered to Australians (as at 12 October 2022).
  • Six COVID-19 vaccines now have provisional approval for use in Australia:
    • COMIRNATY (tozinameran) – Pfizer Australia
    • SPIKEVAX (elasomeran) – Moderna Australia
    • SPIKEVAX Bivalent Original/Omicron (elasomeran/imelasomeran) – Moderna Australia
    • VAXZEVRIA – AstraZeneca
    • NUVAXOVID (NVX-CoV2373) – Biocelect on behalf of Novavax
    • COVID-19 Vaccine Janssen (registered but not available in Australia).
  • The Pfizer, AstraZeneca, Moderna (SPIKEVAX only) and Novavax vaccines are part of Australia's national vaccine rollout.
  • Current data suggests the majority of side effects being reported are mild and short lived.
  • Reporting side effects helps build better knowledge about the vaccines and improves how they continue to be used.
  • As COVID-19 vaccines are rolled out, it is natural for people to have questions about how these fit with their regular medicines and healthcare routines.
 

Adverse Medicine Events (AME) Line

The AME Line is for members of the general public to call if they think a medicine or vaccine is causing a problem and they are worried about it. The call is answered by an NPS MedicineWise pharmacist. The pharmacist will ask questions to better understand the concerns and advise if it is necessary to seek further care from a nurse, doctor or other medical service.

All medicine-related side effects are reported back to the Therapeutic Goods Administration. This information contributes to a more accurate understanding of a medicine or vaccine safety profile.

Contacting the AME Line

Call 1300 134 237 from anywhere in Australia.  Monday–Fridays 9am–5pm AEDT/AEST.

Please note that the AME Line is not for emergencies

If you have concerns about your medicines arising from an overdose or suspected poisoning, call the Poisons Information Centre, 24 hours a day on 13 11 26

For general emergencies call 000.

Read more about the AME Line

 

COVID-19 vaccine FAQs

<img src=

NPS MedicineWise have received many questions about currently available COVID-19 vaccines. Here are answers to some of our most frequently asked questions.

Read the full article

 

COVID-19 vaccine booster doses

<img src=

As new strains of the COVID-19 virus emerge, booster doses can protect from severe illness and hospitalisation. This article addresses some common questions about booster doses for COVID-19 vaccines.

Read the full article

 

Talking with hesitant parents and carers about COVID-19 vaccines and their children

<img src=

This article expands on a podcast conversation recorded on October 2021, between NPS MedicineWise medical advisor Dr Caroline West and internationally recognised expert in vaccination uptake Professor Julie Leask.

Read the full article

Listen to the podcast

 

I'm fully vaccinated against COVID-19 - now what?

<img src=

So, you’re fully vaccinated. Find out more about what this means and how much risk you face from the COVID-19 virus and its variants. The information in this article reflects current evidence and may change as more becomes known about current and new vaccines, as well as emerging variants.

Read the full article

 

COVID-19 vaccination in children and adolescents

<img src=

Vaccination against COVID-19 is recommended for everyone in Australia aged 5 years and above. 

Different vaccines are currently approved for different age groups. These recommendations and approvals reflect the information that has been gathered on the safety, efficacy (how well it works in clinical trials) and effectiveness (how well it works in the real world) of each vaccine.

This article discusses the evidence supporting vaccine use in adolescents aged 12–17 years, and explains the current situation for children under 12 years of age.

Read the full article

 

COVID-19 vaccination side effects: how to manage and when to report them

COVID-19 vaccinations are an important part of the national strategy to protect our health during the current pandemic and into the future.

As with other vaccines, some people may experience mild and temporary side effects after a COVID-19 vaccination.

This article explains what to expect, how to manage any symptoms, how to report side effects and why reporting them is an important part of ensuring the safety of all vaccines, including the COVID-19 vaccine.

Read the full article

 

Influenza vaccines and COVID-19: what you need to know in 2022

This year, with all the focus on the COVID-19 vaccine rollout, it’s easy to forget about another important vaccine – your annual flu jab. It is important to take action to be protected against both of these potentially severe infections.

  • What do we know about influenza in 2022?
  • Will the flu vaccination protect me from getting COVID-19?
  • How should I time the COVID-19 vaccine with the influenza vaccine?

Read the full article

 

Vaccines and COVID-19

Several effective vaccines have been developed to prevent people from becoming seriously ill, or dying, from COVID-19. In Australia, everyone aged 5 years and over is eligible for a free COVID-19 vaccination.

Read the full article

 

Other articles

Australian Prescriber logo

Elasomeran for prevention of COVID-19

Aust Prescr 2021: DOI: 10.18773/austprescr.2021.048

Read the full article

BNT162b2 vaccine for prevention of COVID-19

Aust Prescr 2021;44:57-8

Read the full article

ChAdOx1-S vaccine for prevention of COVID-19

Aust Prescr 2021;44:59-61

Read the full article